8-K: Amarin Corporation Faces Nasdaq Delisting Risk After Share Price Falls Below $1 Threshold

Amarin Corporation has received a notice from Nasdaq that its share price has fallen below the required $1.00 minimum, placing it at risk of delisting.

Summary

• Amarin Corporation received a deficiency letter from Nasdaq on May 24, 2024, because its American Depositary Shares (ADSs) have traded below $1.00 for 30 consecutive business days.
• This violates Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Market.
• Amarin has 180 calendar days, until November 20, 2024, to regain compliance by having its ADS price close at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved by November 20, 2024, Amarin may be granted a second 180-day period if it transfers its listing to the Nasdaq Capital Market and meets other listing requirements.
• There is no guarantee that Amarin will be able to regain compliance with the minimum bid price requirement.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the potential for delisting, which is a major concern for investors.

Positives

• Amarin's shares will continue to trade on the Nasdaq Global Market under the symbol AMRN for now.
• The company has been given 180 days to regain compliance, providing time to address the issue.
• A second 180-day compliance period is possible if the company transfers to the Nasdaq Capital Market.

Negatives

• Amarin's share price has fallen below the minimum $1.00 threshold required for continued listing on the Nasdaq Global Market.
• The company is at risk of being delisted from the Nasdaq if it does not regain compliance by November 20, 2024.
• There is no guarantee that Amarin will be able to regain compliance with the minimum bid price requirement.

Risks

• Amarin faces the risk of delisting from the Nasdaq if its share price does not recover above $1.00 within the given timeframe.
• The company's ability to regain compliance is uncertain, and there is no guarantee of success.
• Delisting could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

Amarin intends to monitor its share price and consider options to regain compliance with Nasdaq listing requirements, but there is no assurance of success.

Management Comments

• The Company intends to actively monitor the closing bid price for its ADSs and may, if appropriate, consider available options to resolve the deficiency and regain compliance with the Bid Price Requirement.

Industry Context

This announcement highlights the challenges faced by pharmaceutical companies with fluctuating stock prices and the importance of maintaining compliance with exchange listing requirements. Many companies in the sector face similar pressures.

Comparison to Industry Standards

• Many biotech and pharmaceutical companies, especially those in the development stage, face similar challenges with maintaining share price above minimum listing requirements.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting risks due to low share prices.
• The Nasdaq minimum bid price rule is a common hurdle for smaller cap companies in the sector.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in share value.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Amarin will monitor its share price.
• Amarin may consider options to regain compliance with Nasdaq listing requirements.
• Amarin may need to transfer to the Nasdaq Capital Market if it cannot regain compliance by November 20, 2024.

Key Dates

Keywords

delisting, Nasdaq, compliance, share price, minimum bid price, AMRN, Amarin Corporation, ADS